Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas P Ahern

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2019
Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort StudyThomas P Ahern, Anne Broe, Timothy L Lash, et al.
American Journal of Epidemiology|December 19, 2016
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of HeterozygosityThomas P Ahern, Daniel L Hertz, Per Damkier, et al.
Acta Oncologica (Stockholm, Sweden)|June 7, 2017
Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort studyDeirdre P Cronin-Fenton, Anders Kjærsgaard, Thomas P Ahern, et al.
BMJ Open|August 3, 2018
Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in DenmarkLindsay J Collin, Deirdre P Cronin-Fenton, Thomas P Ahern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort studyGitte Vrelits Sørensen, Patricia A Ganz, Steven W Cole, et al.
Acta Oncologica (Stockholm, Sweden)|February 17, 2010
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifenTimothy L Lash, Deirdre Cronin-Fenton, Thomas P Ahern, et al.
Journal of the National Cancer Institute|February 18, 2011
CYP2D6 inhibition and breast cancer recurrence in a population-based study in DenmarkTimothy L Lash, Deirdre Cronin-Fenton, Thomas P Ahern, et al.
Pharmacoepidemiology and Drug Safety|May 14, 2025
Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian Joint Modeling ApproachKirsten M Woolpert, Deirdre P Cronin-Fenton, Per Damkier, et al.
Anesthesiology|July 18, 2020
Body Habitus and Dynamic Surgical Conditions Independently Impair Pulmonary Mechanics during Robotic-assisted Laparoscopic SurgeryWilliam G Tharp, Serena Murphy, Max W Breidenstein, et al.
Acta Oncologica (Stockholm, Sweden)|October 24, 2018
Expression of survivin does not appear to influence breast cancer recurrence riskLindsay J Collin, Deirdre P Cronin-Fenton, Thomas P Ahern, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2019
Phthalate Exposure and Breast Cancer Incidence: A Danish Nationwide Cohort StudyThomas P Ahern, Anne Broe, Timothy L Lash, et al.
American Journal of Epidemiology|December 19, 2016
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of HeterozygosityThomas P Ahern, Daniel L Hertz, Per Damkier, et al.
Acta Oncologica (Stockholm, Sweden)|June 7, 2017
Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort studyDeirdre P Cronin-Fenton, Anders Kjærsgaard, Thomas P Ahern, et al.
BMJ Open|August 3, 2018
Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in DenmarkLindsay J Collin, Deirdre P Cronin-Fenton, Thomas P Ahern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort studyGitte Vrelits Sørensen, Patricia A Ganz, Steven W Cole, et al.
Acta Oncologica (Stockholm, Sweden)|February 17, 2010
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifenTimothy L Lash, Deirdre Cronin-Fenton, Thomas P Ahern, et al.
Journal of the National Cancer Institute|February 18, 2011
CYP2D6 inhibition and breast cancer recurrence in a population-based study in DenmarkTimothy L Lash, Deirdre Cronin-Fenton, Thomas P Ahern, et al.
Pharmacoepidemiology and Drug Safety|May 14, 2025
Drug Interactions With Tamoxifen and Treatment Effectiveness in Premenopausal Breast Cancer Patients: A Bayesian Joint Modeling ApproachKirsten M Woolpert, Deirdre P Cronin-Fenton, Per Damkier, et al.
Anesthesiology|July 18, 2020
Body Habitus and Dynamic Surgical Conditions Independently Impair Pulmonary Mechanics during Robotic-assisted Laparoscopic SurgeryWilliam G Tharp, Serena Murphy, Max W Breidenstein, et al.
Acta Oncologica (Stockholm, Sweden)|October 24, 2018
Expression of survivin does not appear to influence breast cancer recurrence riskLindsay J Collin, Deirdre P Cronin-Fenton, Thomas P Ahern, et al.
Pageof 11